- Kirin Holdings and Kirin’s Australian group company Blackmores have jointly developed a product designed to enhance cognitive performance.
- Formulated with Cognizin® Citicoline, a citicoline ingredient from Kyowa Hakko Bio Co., Ltd., a Kirin Group company.
- This product is manufactured at Blackmores’ Braeside site in Australia and will be initially launched in Australia and New Zealand from late July 2026.
TOKYO--BUSINESS WIRE--
Kirin Holdings Company, Limited (Kirin Holdings)(TOKYO:2503) and Blackmores Limited (Blackmores), Kirin’s group company and Australia's leading natural health company, are proud to announce the launch of Blackmores Cognition Ultra in Australia and Blackmores Ultra Brain Care in New Zealand. This new supplement is formulated with Cognizin® Citicoline, a scientifically supported ingredient from Kyowa Hakko Bio Co., Ltd., a Kirin Group company, and is Blackmores’ first product designed to enhance cognitive performance. This product is made at Blackmores’ Braeside manufacturing site and will be available from late July in pharmacies in New Zealand, as well as on Blackmores’ e-commerce platform in Australia, followed by the launch in Australian pharmacies from September.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260723848766/en/
Blackmores Cognition Ultra (Australia)
Since Blackmores joined the Kirin Group in August 2023, the Group has strengthened its initiatives to address consumer health needs in the Asia-Pacific (APAC) region, while exploring value creation opportunities and business synergies in the Health Science domain. This product was made possible by combining Blackmores’ consumer insight, product development capabilities, and regulatory capabilities with Kyowa Hakko Bio’s strength in providing ingredients backed by science-based evidence.
Cognitive health is essential for quality of daily life*1. In recent years, there has been growing interest in age-related changes in cognitive function and early efforts to maintain brain health. Studies suggest that decline in cognitive function may start in midlife and international organizations, including the World Health Organization (WHO), have highlighted the importance of maintaining brain health across the life course*2.
1. National Institute on Aging (NIH) Cognitive Health and Older Adults; |
2. WHO Optimizing brain health across the life course: WHO position paper; |
This product will be launched as a supplement that supports the health of consumers interested in cognitive function, in accordance with applicable regulations in each country and region. Through this launch, the Kirin Group will continue to advance its Creating Shared Value (CSV) management, which aims to create both social and economic value, while pursuing further growth of the Health Science Business in the Asia-Pacific (APAC) region.
Alastair Symington, Senior Executive Officer, Kirin Holdings; President, Kirin Health Science International; and CEO & Managing Director, Blackmores Limited, said: “Our purpose is to support people’s long-term health by combining the best of nature with science. Leading research highlights the importance of caring for brain health to maintain cognitive function as we age. Blackmores Cognition Ultra and Blackmores Ultra Brain Care are designed to support brain performance, health and function as part of a healthy lifestyle. Together, they reflect our commitment to helping people live well for the long term."
Product Overview
Blackmores Cognition Ultra (Australia)・Blackmores Ultra Brain Care (New Zealand)
This product is a supplement formulated with Cognizin®, a citicoline ingredient from Kyowa Hakko Bio. “Blackmores Cognition Ultra” in Australia and “Blackmores Ultra Brain Care” in New Zealand share the same formulation and will be launched with labeling that complies with the applicable regulations in each country and region.
Package
Designed to communicate Blackmores’ quality and product characteristics, featuring the Cognizin® logo.
Recommended Daily Intake
Two tablets once daily, or as prescribed by a health professional.
Formulation
Contains 250 mg of Cognizin® per tablet.
“Blackmores Cognition Ultra” in Australia and “Blackmores Ultra Brain Care” in New Zealand share the same formulation.
Characteristics
The following are the main descriptions planned for display in the launch markets, in accordance with the regulations of each country and region.
Blackmores Cognition Ultra (Australia)
- Enhance cognitive performance
- Improve memory recall and attention
- Support information processing
- Support focus and clarity
- Support brain function
- Support brain health in ageing individuals
- Caffeine free
Blackmores Ultra Brain Care (New Zealand)
- Support daily brain performance, health & function
- Support mental focus for work/study
- Support mental clarity
- Readily absorbed to support vital brain function
- Support brain clarity in ageing adults
- Caffeine free
Product Details | |
1. Product Name and Pack Size | |
A. Blackmores Cognition Ultra (Australia) | 30 tablets |
B. Blackmores Ultra Brain Care (New Zealand) | 30 tablets |
2. Sales Markets | |
A. Australia | |
B. New Zealand | |
3. Launch Date | |
A, B. Late July 2026 | |
4. Sales channels | |
A. Blackmores Australia e-commerce platform https://www.blackmores.com.au/products/cognition-ultra | |
A. Pharmacy channel from September 2026 onwards | |
B. Pharmacy channel | |
5. Retail price | |
Blackmores official e-commerce platform price | |
A. AUD 45.00 per pack | |
B. NZD 41.99 per pack | |
Retail prices at pharmacies will be announced by the respective retailers at the time of launch. | |
6. Regulatory Note | |
In Australia, Cognizin® Citicoline has been listed as a new ingredient by the Therapeutic Goods Administration (TGA), Australia’s health authority. | |
Product claims and indications are subject to, and may vary by, regulatory jurisdiction. | |
About Kirin Holdings
Kirin Holdings Company, Limited is a global company operating across three core business domains spanning Alcoholic Beverages, Non-alcoholic Beverages & Health Science, and Pharmaceuticals. The company traces its roots to Japan Brewery, established in 1885, which later became Kirin Brewery in 1907. Since then, Kirin has expanded its business operations by leveraging fermentation and biotechnology as core strengths. The company entered the pharmaceutical field in the 1980s, which has since grown into a global business. In 2007, the company transitioned to a pure holding company structure as Kirin Holdings, and it is now strengthening its Non-alcoholic Beverages & Health Science domain.
Under its long-term vision “Innovate2035!”, the Kirin Group is focused on creating value that encourage behavioral change among consumers and patients, creating new lifestyle habits in the areas of food and health. With a unique business portfolio spanning Alcoholic Beverages, Non-alcoholic Beverages & Health Science, and Pharmaceuticals, the Group will further expand group-wide initiatives that support both mental and physical well-being.
The Kirin Group will continue to advance innovation through the combined strength of its people and technology, creating both social and economic value as a global leader in CSV*, while pursuing sustainable, long-term growth in corporate value.
*Creating Shared Value: combined added value for consumers as well as for society at large. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260723848766/en/
Contact details:
Press Contact
Corporate Communication Department
Kirin Holdings Company, Limited www.kirinholdings.com/en/
Nakano Central Park South, 4-10-2 Nakano, Nakano-ku, Tokyo
Media contact https://faq.kirin.co.jp/form/kh_10_en.html
Tel : +81-3-6837-7028 e-mail: [email protected]
